7071 - 7080 of 8586 Results
Title
Year
- Exploration of Fluorinated Pyrazolidine‐3,5‐Diones for Positron Emission Tomography Imaging of the P2Y12 Receptor in the Central Nervous System2025RESTRICTEDTitle: Exploration of Fluorinated Pyrazolidine‐3,5‐Diones for Positron Emission Tomography Imaging of the P2Y12 Receptor in the Central Nervous SystemJournal Name: ChemMedChemPublisher: WileyVol:Issue #:Start Page: e202500483End Page: e202500483Publication Date:Open Access(OA) Status: RESTRICTEDLicense: cc-by-nc-ndDOI - Digital Object Identifier: 10.1002/cmdc.202500483Citation Count: 0
-
OPENTitle: Bradykinesia and Its Progression Are Related to Interhemispheric Beta CoherenceJournal Name: Annals of NeurologyPublisher: WileyVol: 93Issue #: 5Start Page: 1029End Page: 1039Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1002/ana.26605Best OA location URL: https://www.ncbi.nlm.nih.gov/pmc/articles/10191890Citation Count: 12
- 17α-Ethynyl-androst-5-ene-3β,7β,17β-triol (HE3286) Is Neuroprotective and Reduces Motor Impairment and Neuroinflammation in a Murine MPTP Model of Parkinson’s Disease2012OPENTitle: 17α-Ethynyl-androst-5-ene-3β,7β,17β-triol (HE3286) Is Neuroprotective and Reduces Motor Impairment and Neuroinflammation in a Murine MPTP Model of Parkinson’s DiseaseJournal Name: Parkinson's DiseasePublisher: WileyVol: 2012Issue #:Start Page: 1End Page: 8Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1155/2012/969418Best OA location URL: https://downloads.hindawi.com/journals/pd/2012/969418.pdfCitation Count: 10
-
OPENTitle: Alternative splicing expands the clinical spectrum of NDUFS6-related mitochondrial disordersJournal Name: Genetics in MedicinePublisher: Elsevier BVVol: 26Issue #: 6Start Page: 101117End Page: 101117Publication Date:Open Access(OA) Status: OPENLicense: cc-by, cc-by, cc-byDOI - Digital Object Identifier: 10.1016/j.gim.2024.101117Best OA location URL: https://doi.org/10.1016/j.gim.2024.101117Citation Count: 2
- Direct targeting of wild-type glucocerebrosidase by antipsychotic quetiapine improves pathogenic phenotypes in Parkinson’s disease models2021OPENTitle: Direct targeting of wild-type glucocerebrosidase by antipsychotic quetiapine improves pathogenic phenotypes in Parkinson’s disease modelsJournal Name: JCI InsightPublisher: American Society for Clinical InvestigationVol: 6Issue #: 19Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1172/jci.insight.148649Best OA location URL: http://insight.jci.org/articles/view/148649/files/pdfCitation Count: 7
-
RESTRICTEDTitle: Distal Covalent Targeting Suppresses Signaling of Oncogenic K-Ras(G13C) in Cancer CellsJournal Name: ACS Chemical BiologyPublisher: American Chemical Society (ACS)Vol: 20Issue #: 7Start Page: 1696End Page: 1706Publication Date:Open Access(OA) Status: RESTRICTEDLicense: cc-by-nc-nd, cc-by-nc-ndDOI - Digital Object Identifier: 10.1021/acschembio.5c00249Citation Count: 0
-
OPENTitle: CSF Aβ42 and tau in Parkinson's disease with cognitive impairmentJournal Name: Movement DisordersPublisher: WileyVol: 25Issue #: 15Start Page: 2682End Page: 2685Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1002/mds.23287Best OA location URL: https://www.ncbi.nlm.nih.gov/pmc/articles/2978754Citation Count: 173
- The protective effect of LRRK2 p.R1398H on risk of Parkinson's disease is independent of MAPT and SNCA variants2013OPENTitle: The protective effect of LRRK2 p.R1398H on risk of Parkinson's disease is independent of MAPT and SNCA variantsJournal Name: Neurobiology of AgingPublisher: Elsevier BVVol: 35Issue #: 1Start Page: 266.e5End Page: 266.e14Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1016/j.neurobiolaging.2013.07.013Best OA location URL: https://www.sciencedirect.com/science/article/pii/S0197458013003187Citation Count: 38
- Neuroprotection of low dose carbon monoxide in Parkinson’s disease models commensurate with the reduced risk of Parkinson’s among smokers2024OPENTitle: Neuroprotection of low dose carbon monoxide in Parkinson’s disease models commensurate with the reduced risk of Parkinson’s among smokersJournal Name: npj Parkinson's DiseasePublisher: Springer Science and Business Media LLCVol: 10Issue #: 1Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense: cc-by-nc-ndDOI - Digital Object Identifier: 10.1038/s41531-024-00763-6Best OA location URL: https://www.nature.com/articles/s41531-024-00763-6.pdfCitation Count: 12
- Nigral volumetric and microstructural measures in individuals with scans without evidence of dopaminergic deficit2022OPENTitle: Nigral volumetric and microstructural measures in individuals with scans without evidence of dopaminergic deficitJournal Name: Frontiers in NeurosciencePublisher: Frontiers Media SAVol: 16Issue #:Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.3389/fnins.2022.1048945Best OA location URL: https://www.frontiersin.org/articles/10.3389/fnins.2022.1048945/pdfCitation Count: 4